References
- World Health Organization (WHO)Chronic obstructive pulmonary diseaseWHO Fact Sheet no. 315; 2008. Available from: www.who.int/mediacentre/factsheets/fs315/en
- ManninoDMHomaDMAkinbamiLJFordESReddSCChronic obstructive pulmonary disease surveillance – United States, 1971–2000MMWR Surveill Summ200251116
- US National Heart Lung and Blood Institute (NHLBI)Morbidity and Mortality: 2007 Chartbook on cardiovascular, lung, and blood diseasesBethesda, MDNational Institutes of Health2007
- American Lung AssociationChronic obstructive pulmonary disease (COPD) fact sheetAmerican Lung Association; 2008 Available from: www.lungusa.org/site/apps/nlnet/content3.aspx?c=dvLUK9O0E&b=2058829&content_id={EE451F66-996B-4C23-874D-BF66586196FF}¬oc=1
- CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH StudyAm J Respir Crit Care Med200817832232318676961
- SeemungalTARDonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Resp Crit Care Med1998157141814229603117
- StanfordRHShenYMcLaughlinTCost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitalsTreat Respir Med2006534334916928147
- AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD2009632032919863361
- CalverlyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
- FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbationsRespir Med20081021099110818614347
- HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus Inhaler for the treatment of COPDChest200312483484312970006
- KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717514414917053207
- MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20021661084109112379552
- SzafranskiWCukierARamirezAEfficacy and safety of budenoside/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J200321748112570112
- AkazawaMHayflingerDCStanfordRHBlanchetteCMEconomic assessment of initial maintenance therapy for chronic obstructive pulmonary disease from a managed care perspectiveAm J Manage Care2008142132
- DeleaTEHagiwaraMDalalAAStanfordRHBlanchetteCMHealth care use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol versus other inhaled maintenance therapiesCurr Med Res Opin20092511319210134
- RascatiKLAkazawaMJohnsrudMStanfordRHBlanchetteCMComparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimenClin Ther2007291203121317692734
- HalpinDMenjogeSVielKPatient level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalizationsPrim Care Respir J20091810611319407916
- NurmagambetovTAtherlyAWilliamsSHolguinFManninoDMReddSCWhat is the cost to employers of direct medical care for chronic obstructive pulmonary diseaseCOPD2006320320917361501
- 2007 Drug Topics Redbook Annual111th edMontvale NJThompson Healthcare2007
- EarnshawSRWilsonMRDalalAACost effectiveness of fluticasone propionate/salmeterol (500/50 μg) in the treatment of COPDRespir Med2009103122119010652
- StrasselsSASmithDHSullivanSDMahajanPSThe costs of treating COPD in the United StatesChest200111934435211171708
- TashkinDPCelliBSennSUPLIFT study investigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
- American Thoracic Society/European Respiratory Society (ATS/ERS)Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2.New YorkAmerican Thoracic Society2004 [updated 2005 September 8]. Available from: www.thoracic.org/go/copd
- Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseaseGlobal Initiative for Chronic Obstructive Pulmonary Disease; 2007. [Updated 2008]. Available from: URL: http://www.goldcopd.com/GuidelinesResources.asp